Assessment of Quality of Life in Non-small-cell Lung Cancer Patients by Patient-reported Outcome (PRO) -A Review of Phase III Trials-

DOI Web Site 26 References
  • Kumihashi Yuki
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Hanibuchi Masaki
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Tomimoto Hideki
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Azuma Momoyo
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Kanematsu Takanori
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Kakiuchi Soji
    Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Goto Hisatsugu
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Tada Hiroya
    Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Nishioka Yasuhiko
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Sone Saburo
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima Graduate School

Bibliographic Information

Other Title
  • 非小細胞肺癌患者のｐａｔｉｅｎｔ－ｒｅｐｏｒｔｅｄ　ｏｕｔｃｏｍｅ（ＰＲＯ）評価法の現状と問題点‐第ＩＩＩ相臨床試験論文のｒｅｖｉｅｗ‐

Search this article

Description

Background. Recently, much attention has been paid to patient-reported outcomes (PRO) as self-administered assessment instruments in the quality of life evaluation of cancer patients. Objective and Methods. In the present study, we reviewed a total of 24 published articles (1999 through 2007) which reported phase III clinical trials for non-small-cell lung cancer, all of which set PRO assessment as one of the study endpoints. We evaluated the questionnaires used for PRO assessment, assessment intervals and patient compliance with PRO assessment in each trial. Several kinds of questionnaires were used in most PRO assessment trials. Results. The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) was used in 17 out of 24 trials. PRO was commonly assessed before each course of chemotherapy, at the end of chemotherapy and 1-3 months after treatment cessation. Patient compliance at the final assessment had significantly deteriorated compared with baseline PRO assessment, presumably due to the increment of missing data. Conclusion. Further studies which evaluate the problems of PRO assessment as a surrogate marker of therapeutic efficacy in lung cancer patients are warranted.<br>

Journal

  • Haigan

    Haigan 50 (6), 791-802, 2010

    The Japan Lung Cancer Society

References(26)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top